An interventional study of Pyridoxal 5'-Phosphate (100 mg) and Placebo in Autism, sponsored by University of Reading. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Reading · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Autistic Disorder with a site in United Kingdom — 10 open to participants now, 14 under way, none of them phase 3. Autistic Disorder · United Kingdom.
Among the 37 studies in Autistic Disorder with a site in United Kingdom, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2024, is one of 19 with no phase, reaches primary completion later than 10 of the 13 other live ones, and was the 26th registered.
1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →10 of the 37 studies in Autistic Disorder with a site in United Kingdom are open now. Recruiting first, the newest first:
Canterbury Christ Church University · Sites in United Kingdom
Ages 18+
Prof Simon Baron-Cohen · Sites in United Kingdom
Ages 7–11
University of Manchester · Sites in United Kingdom
Ages 11–16
Aberystwyth University · Sites in United Kingdom
Ages 10–24 · Healthy volunteers
Sussex Community NHS Foundation Trust · Sites in United Kingdom
Ages 6–16
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 50 across 814 interventional studies indexed under Autistic Disorder.
Median enrollment 69 across the 21 interventional studies, 163 across the 16 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 37 have an industry lead sponsor. The 10 most frequent:
University of Reading is the lead sponsor of 151 studies on the registry; 22 are open to participants now.
University of Reading has 1 study filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Autistic Disorder with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07498049University of NottinghamCFT Guided Self-help Intervention: Parents of Autistic Children | 2026-11 |
| NCT07630376Canterbury Christ Church UniversityEvaluating a Workbook to Promote Autistic Wellbeing | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Autistic Disorder with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to explore the effect of Vitamin B6 supplementation on anxiety sensory hyperreactivity in autistic adults. Researchers will compare a placebo group to high-dose Vitamin-B6 to see if vitamin B6 reduce anxiety and sensory reactivity differences in autism.
The main question it aims to answer is:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will consume one high-dose Vitamin B6 100 mg tablet orally once daily for one month. Vitamin B6 will be provided as Pyridoxal-5'-Phosphate (PLP)
Dietary Supplement: Pyridoxal 5'-Phosphate (100 mg)
Participants will consume a Placebo tablet matching the appearance of the Vitamin B6 tablets in the Experimental arm orally once daily for one month.
Other: Placebo
100 mg Pyridoxal 5'-Phosphate tablet once daily with food
Also known as: Vitamin B6
Placebo tablet once daily
Also known as: Control group
Sensory hyperreactivity
Sensory hyperreactivity will be measured by a subscale of the Sensory Processing Inventory (SP3D.
Time frame: Baseline and One month
Sensory hyperreactivity
Sensory hyperreactivity will be measured by a subscale of the Comprehensive Autistic Trait Inventory (CATI).
Time frame: Baseline and One month
Anxiety
Anxiety will be measured using the Screen for Adult Anxiety Related Disorders (SCAARED) questionnaire.
Time frame: Baseline and One month
Vitamin B6 status
The concentration of different forms of Vitamin B6 in blood plasma will be measured (Pyridoxal-5'-phosphate, pyridoxine, pyridoxal, pyridoxamine)
Time frame: Baseline and One month
ADHD traits
Adult Attention Deficit Hyperreactivity Disorder Self-Report Scale (ASRS-v1.1)
Time frame: Baseline and One month
Sensory processing differences
These will be measured using the other subscales of the Sensory Processing Inventory (SP3D) that do not constitute the primary sensory hyperreactivity outcome described above.
Time frame: Baseline and One month
Sleep quality
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline and One month
Visual Surround Suppression of contrast perception
Psychophysical measurements of the contrast threshold will be made, which correspond to the minimum physical stimulus contrast that can be reliably detected by an observer. The test measures the increase in the threshold caused by introducing spatial inhibition of the target stimuli, which is a parameter that has been shown to correlate with GABA concentration in the brain (Yoon et al., 2010).
Time frame: Baseline and One month
Surround Suppression of Motion duration detection thresholds
Psychophysical measurements of the motion duration threshold will be made, which correspond to the number of milliseconds an observer requires to detect whether a Gabor patch is drifting left or right. The test measures the increase in the threshold caused by spatial inhibition, which is a parameter that has been shown to differ in various patient groups, including autism (Foss-Feig et al. 2013).
Time frame: Baseline and One month
Binocular Rivalry reversal rate
A test based on presenting ambiguous visual stimuli that cause perceptual reversals; how frequently the perceptual reversals occur is measured and has been shown to be related to GABA levels (Mentch et al., 2019).
Time frame: Baseline and One month
Binocular Rivalry suppression index
A test based on presenting ambiguous visual stimuli that cause perceptual reversals; the proportion of time for which the stimulus appears unclear rather than stable is measured and has been shown to be related to GABA levels (Mentch et al., 2019).
Time frame: Baseline and One month
Measurement of Weber Fraction for size perception
The Weber fraction is the percentage change in a physical quantity required for an observer to reliably detect that a change has occurred, and for a specific stimulus type it is generally a fixed percentage regardless of the magnitude of the stimuli. We will measure the Weber Fraction for visual size perception at four separate starting sizes, and the outcome measure derived from doing that will be a measurement of the stability/instability of the Weber Fraction across the four starting sizes. It has been reported that in autism the general finding of fixed Weber fractions across a range of physical stimuli does not hold (Hadad \& Schwartz, 2019): we are taking the opportunity to replicate this finding.
Time frame: Baseline and One month
Tilt illusion magnitude
Magnitude of the tilt illusion is a correlate of GABA concentration in the occipital cortex (Song et al., 2017).
Time frame: Baseline and One month
Ebbinghaus illusion magnitude
Magnitude of the Ebbinghaus illusion is a correlate of gamma y-Aminobutyric acid (GABA) concentration in the parietal lobe (Song et al. 2017)
Time frame: Baseline and One month
Plan to share: No
Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.
Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 24 months is close to that.
Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Jul 2026 → Nov 2026 and completion Jul 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pyridoxal Phosphate